Johan Sein

589 total citations
17 papers, 490 citations indexed

About

Johan Sein is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Johan Sein has authored 17 papers receiving a total of 490 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Immunology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Johan Sein's work include Immunotherapy and Immune Responses (8 papers), CAR-T cell therapy research (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Johan Sein is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), CAR-T cell therapy research (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Johan Sein collaborates with scholars based in Netherlands, Slovakia and United States. Johan Sein's co-authors include Annemarie Hekman, Florry A. Vyth‐Dreese, Elaine M. Rankin, W J Nooijen, Michael Kersten, Willem J. Nooijen, M.P.W. Gallee, Sjoerd Rodenhuis, Omgo E. Nieweg and R. Somers and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Johan Sein

17 papers receiving 471 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Johan Sein Netherlands 11 316 278 150 147 56 17 490
Szilvia Mosolits Sweden 12 334 1.1× 247 0.9× 148 1.0× 93 0.6× 24 0.4× 15 478
Elizabeth Taras United States 11 338 1.1× 269 1.0× 132 0.9× 93 0.6× 19 0.3× 15 539
Sabine Renoth Germany 8 373 1.2× 294 1.1× 122 0.8× 69 0.5× 76 1.4× 11 536
Cristina Mastini Italy 13 275 0.9× 228 0.8× 246 1.6× 97 0.7× 92 1.6× 15 557
John B. Beard United States 7 168 0.5× 110 0.4× 302 2.0× 121 0.8× 39 0.7× 8 513
Timothy J. O rsquo Brien United States 10 209 0.7× 152 0.5× 376 2.5× 153 1.0× 48 0.9× 10 651
Jeffrey Schlom United States 9 164 0.5× 174 0.6× 122 0.8× 156 1.1× 27 0.5× 11 391
Aline Martayan Italy 13 287 0.9× 122 0.4× 148 1.0× 45 0.3× 70 1.3× 24 546
Doris Rau Germany 11 267 0.8× 435 1.6× 263 1.8× 370 2.5× 17 0.3× 14 673
Takako Tsujimoto Japan 9 248 0.8× 159 0.6× 160 1.1× 49 0.3× 40 0.7× 9 513

Countries citing papers authored by Johan Sein

Since Specialization
Citations

This map shows the geographic impact of Johan Sein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan Sein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan Sein more than expected).

Fields of papers citing papers by Johan Sein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johan Sein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan Sein. The network helps show where Johan Sein may publish in the future.

Co-authorship network of co-authors of Johan Sein

This figure shows the co-authorship network connecting the top 25 collaborators of Johan Sein. A scholar is included among the top collaborators of Johan Sein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johan Sein. Johan Sein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Vyth‐Dreese, Florry A., et al.. (2010). Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma. Clinical & Experimental Immunology. 162(3). 447–459. 2 indexed citations
2.
Bins, Adriaan D., Henk Mallo, Johan Sein, et al.. (2007). Phase I Clinical Study With Multiple Peptide Vaccines in Combination With Tetanus Toxoid and GM-CSF in Advanced-stage HLA-A*0201-positive Melanoma Patients. Journal of Immunotherapy. 30(2). 234–239. 19 indexed citations
3.
Jong, Daphne de, Axel Bex, Trees A. M. Dellemijn, et al.. (2005). Infiltration of Activated Dendritic Cells and T Cells in Renal Cell Carcinoma Following Combined Cytokine Immunotherapy. European Urology. 48(3). 527–533. 25 indexed citations
4.
Luiten, Rosalie M., Esther W. M. Kueter, Wolter J. Mooi, et al.. (2005). Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With AutologousGM-CSF–Transduced Tumor Cells in Metastatic Melanoma Patients. Journal of Clinical Oncology. 23(35). 8978–8991. 90 indexed citations
5.
Bins, Adriaan D., Sjoerd G. Elias, Johan Sein, et al.. (2004). On the Role of Melanoma-Specific CD8+ T-Cell Immunity in Disease Progression of Advanced-Stage Melanoma Patients. Clinical Cancer Research. 10(14). 4754–4760. 41 indexed citations
6.
Batchelor, D., Michael Kersten, Florry A. Vyth‐Dreese, et al.. (2003). Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma. British Journal of Cancer. 88(2). 175–180. 36 indexed citations
7.
Jansen, Slinger, Gerard Groenewegen, Henk Mallo, et al.. (2003). Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma. British Journal of Cancer. 88(9). 1346–1351. 30 indexed citations
8.
Vyth‐Dreese, Florry A., W J Nooijen, Johan Sein, et al.. (2002). Reinfusion of Autologous Lymphocytes With Granulocyte-Macrophage Colony-Stimulating Factor Induces Rapid Recovery of CD4+ and CD8+ T Cells After High-Dose Chemotherapy for Metastatic Breast Cancer. Journal of Clinical Oncology. 20(1). 58–64. 10 indexed citations
9.
Gast, G C de, Heinz‐Josef Klümpen, Florry A. Vyth‐Dreese, et al.. (2000). Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.. PubMed. 6(4). 1267–72. 48 indexed citations
10.
Hooijberg, Erik, Marjan J.W. Visseren, Paul C.M. van den Berk, et al.. (1996). Lysis of Syngeneic Tumor B Cells by Autoreactive Cytotoxic T Lymphocytes Specific for a CD 19 Antigen-Derived Synthetic Peptide. Journal of Immunotherapy. 19(5). 346–356. 5 indexed citations
11.
Hooijberg, Erik, et al.. (1996). Characterization of a Series of Isotype Switch Variants of a New CD20 Monoclonal Antibody. Hybridoma. 15(1). 23–31. 10 indexed citations
12.
13.
Hooijberg, Erik, Johan Sein, A. A. M. Hart, et al.. (1995). Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.. PubMed. 55(12). 2627–34. 47 indexed citations
14.
Hekman, Annemarie, Florry A. Vyth‐Dreese, Cornelis J.M. Melief, et al.. (1995). Treatment of low-grade non-Hodgkin?s lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. Cancer Immunology Immunotherapy. 40(1). 37–47. 7 indexed citations
15.
Vlasveld, Lodewijk Th., E. van de Wiel-van Kemenade, Annemiek J. de Boer, et al.. (1993). Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancer. Cancer Immunology Immunotherapy. 36(3). 210–213. 4 indexed citations
16.
Vlasveld, Lodewijk Th., Jos H. Beijnen, Johan Sein, et al.. (1993). Reconstitution of recombinant interleukin-2 (rIL-2): a comparative study of various rIL-2 muteins. European Journal of Cancer. 29(14). 1977–1979. 11 indexed citations
17.
Hekman, Annemarie, Wim M.J. Vuist, Johan Sein, et al.. (1991). Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunology Immunotherapy. 32(6). 364–372. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Szilvia Mosolits Breakdown of academic impact, for papers by Elizabeth Taras Breakdown of academic impact, for papers by Sabine Renoth Breakdown of academic impact, for papers by Cristina Mastini Breakdown of academic impact, for papers by John B. Beard Breakdown of academic impact, for papers by Timothy J. O rsquo Brien Breakdown of academic impact, for papers by Jeffrey Schlom Breakdown of academic impact, for papers by Aline Martayan Breakdown of academic impact, for papers by Doris Rau Breakdown of academic impact, for papers by Takako Tsujimoto
Rankless by CCL
2026